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Sys temic che mo ther apy of ad vanced colorectal can cer
(CRC) adds around 9% 5-year sur vival rate with mod ern
che mo ther apy. 1 Such an out come is sub stan tially better
when sur gi cal re sec tion of liver metastases is per formed on
very well se lected pa tients. The shrink age of tu mor with
proper med i cal treat ment has im proved over time, more
and more re sec tions of liver metastases that were ini tially
con sid ered unresectable are be ing per formed by spe cial -
ized sur geons. 
The par a digm “better re sponses -> more re sec tions ->
better ef fi cacy”2 is en cour ag ing, to the point that
resectability is con sid ered a po ten tial pri mary end point of
clin i cal tri als. We could see why such an end point is so at -
trac tive to pa tients and phy si cians, but at the same time so
mis lead ing and bi ased that it should not be used as the pri -
mary end point in clin i cal tri als. What drives our ther a peu -
tic choices in clin i cal prac tice is not the me dian ef fect, or
the haz ard ra tio for sur vival, or the pro gres sion-free
survival (PFS) ad van tage with a cer tain treat ment over an -
other, rather it is an in di vid ual pa tient could be “an out lier,”
ie, he or she might de rive a sig nif i cant ben e fit from ther apy. 
In this re gard, the abil ity of newer com bi na tions to en able
sur gi cal re sec tion of met a static le sions that were not ini -
tially resectable is very at trac tive.3 Fol low ing rad i cal sur -
gery, even those pa tients with ini tially unresectable dis ease
will have a 30% chance of long-term sur vival,4 which is
sim i lar to that of pa tients who un dergo pri mary re sec tion.5
Of fer ing pa tients with met a static colorectal can cer a chance 
of cure rep re sents the main driv ing force of our clin i cal
prac tice. How ever, given the high prob a bil ity that dis ease
will re cur within a few months of ma jor liver sur gery, is
resectability by it self a rel e vant enough out come to pur sue?
“Resectability” in di cates a state of po ten tial re sec tion, it
does not im ply that the pa tient has had the tu mor com -
pletely re moved, is alive, well, and free of dis ease. Thus, it
is im por tant to rec og nize that resectability is just the first
stage of a se quen tial pro cess con sist ing of the fol low ing
suc ces sive steps: 
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Table 1 illustrates the lack of compelling data available from clinical trials on this issue; the reported outcomes, in
fact, refer only to patients who successfully underwent resection with curative intent, not to all patients considered
eligible for radical surgery after “conversion chemotherapy.” 
1. the patient undergoes surgery, 
2. the surgeon attempts to resect the tumor (up to 20% of
these procedures result in an aborted open-close
operation due to the presence of peritoneal metastases), 
3. the tumor is resected by the surgeon, 
4. all tumor deposits are resected with adequate margins, 
5. the pathologist confirms that an R0 resection was
performed, 
6. the patient fully recovers from the procedure.
In gen eral, 10–20 of 100 pa tients with ini tially unresectable 
dis ease will be con sid ered el i gi ble for liver sur gery fol low -
ing neoadjuvant treat ment. Only half of these pa tients,
how ever, will be alive, well, and dis ease free af ter sur gery.
And when all is said and done, how long might the dis -
ease-free state be ex pected to last af ter sur gery? For ex am -
ple, in a trial by Alberts et al spe cif i cally de signed to as sess
the ac tiv ity of FOLFOX4 as first-line ther apy for pa tients
with liver-lim ited metastases from colorectal can cer, tu mor
shrink age oc curred in 60% of the ini tial 42 pa tients, and re -
sec tion was at tempted in 40%. Among those pa tients who
un der went sur gery, 33% had an R0 re sec tion, but dis ease
re curred in 40% of these pa tients within 12 months. This
casts doubts on the real value of such an ag gres sive treat -
ment plan in clud ing com bi na tion che mo ther apy and ma jor
sur gery. 
Thus, resectability is gain ing more and more pop u lar ity
among in ves ti ga tors, based on very shaky sci en tific
ground. Let’s con sider the in trin sic pe cu liar i ties of a study
that would com pare two treat ments, pur su ing resectability
of ini tially unresectable liver metastases as its pri mary end
point, and let’s con sider the chal lenges that such a study
would pres ent. There are two types of er rors in clin i cal tri -
als—ran dom er ror and bias. Ran dom er ror is due to the nat -
u ral vari abil ity of bi o log i cal and clin i cal phe nom ena; bias is 
due to a spe cific se lec tion that clin i cal in ves ti ga tors may
make. The pur pose of a clin i cal pro to col is to min i mize
these two types of er rors. Ac cru ing a large num ber of pa -
tients and ran dom iz ing them are the most ef fec tive means
of min i miz ing vari abil ity (ran dom er ror), whereas hav ing
strict el i gi bil ity and ex clu sion cri te ria and an a lyz ing data on 
an in ten tion-to-treat ba sis are key to min i miz ing bias. In the 
case of a trial eval u at ing neoadjuvant ther apy of ini tially
unresectable liver metastases, these ba sic con cepts con sti -
tute pro hib i tive chal lenges.
Ac cru ing a large num ber of pa tients el i gi ble for such a
study is very dif fi cult due to the in trin sic com plex ity of any
multimodality treat ment trial. Yet, this prob lem can be
over come.
The key el i gi bil ity cri te rion for a trial like this is that the dis -
ease is unresectable at the time of study en try, but may be -
come resectable if the le sions shrink suf fi ciently af ter treat -
ment ment. There is noth ing more vari able than the eval u a -
tion of resectability.7 Ac cess ing dif fi cult an a tomic lo ca tions 
may be pro hib i tive for a gen eral sur geon but still pos si ble
for an ex pe ri enced liver sur geon. The def i ni tion of
“resectable” is chang ing over time.8 Ini tially fo cus ing on
“what co mes out,” it has pro gres sively shifted to ward
“what’s left in,” with “resectable dis ease” con sid ered that
which can be re moved while pre serv ing ad e quate hepatic
re serve. Thus, what con sti tutes “resectable” still re mains
highly sub jec tive.
The temp ta tion not to per form an in ten tion-to-treat anal y sis 
is very strong in these com pli cated con di tions, as best ex -
em pli fied by the EORTC (Eu ro pean Or ga ni za tion for Re -
search and Treat ment of Can cer) trial9 that has gen er ated so 
much de bate re cently.10 We can spec u late that the real hall -
mark of ben e fit is nei ther re sponse nor resectability nor the
R0 re sec tion rate, but rather how long the pa tient shows no
ev i dence of dis ease af ter an R0 re sec tion; to wit, re cur -
rence-free sur vival (RFS). As a ref er ence point, a 6-month
RFS seems too short an in ter val when we en gage in costly
and risky pro grams of pre op er a tive treat ment fol lowed by
sur gery. It is our feel ing that the RFS should be at least 12
months in a sig nif i cant pro por tion of pa tients. Any thing be -
low 25%–30% of pa tients liv ing re lapse-free for a min i -
mum of 12 months would have lit tle clin i cal rel e vance and
would be too costly. This con cept may ap ply both to clin i -
cal prac tice (where ex cep tions can ob vi ously be made) and
trial de sign. Our group is con duct ing a trial where clearly
unresectable ad vanced colorectal can cer pa tients are treated 
with a com bi na tion of three biologics and a che mo ther apy
dou blet, with the “am bi tious” pri mary end point of
12-month RFS in at least 30% of en rolled pa tients. We cer -
tainly have set a very high bar for suc cess. But in light of the 
costs and mor bid i ties of this ap proach we need in no va tive
end points that re al is ti cally merge clin i cal rel e vance with
tox ic ity and cost. The cho sen end point should min i mize
the bias con nected with de fin ing resectability and lead to a
more care ful se lec tion of pa tients for max i mum ben e fit.
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